Synbiotic supplement to lessen schizophrenia symptoms
Part of Mental health clinical trials.
This Phase 2 trial tests whether a “synbiotic” supplement (a mix of probiotics and prebiotics) can reduce symptoms of schizophrenia or schizoaffective disorder. It may help by targeting gut-related immune and inflammation pathways that could affect brain symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 65 years old and able to sign informed consent
- Have a confirmed diagnosis of schizophrenia or schizoaffective disorder
- Still have at least moderately severe symptoms on a symptom rating scale
- Be an outpatient and taking antipsychotic medicine for at least 8 weeks, with no dose changes in the last 21 days
- Speak and read English well enough for study visits and forms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medication that may reduce inflammation in the brain for people with schizophrenia. It focuses on those who have a specific immune marker, which might mean the medication could help with symptoms.
This study tests whether adding a supplement called sodium benzoate to your current antipsychotic medication can improve symptoms in schizophrenia that hasn't responded well to standard treatments. Researchers will measure brain chemistry changes and symptom improvement over time.
This Phase 4 study tests how an anti-inflammatory approach affects people with schizophrenia or schizoaffective disorder who also have signs of body inflammation. It may help by targeting inflammation that could be linked to symptoms for some people.
This study tests a personalized program that combines lifestyle changes with medication to improve daily functioning in people with schizophrenia, bipolar disorder, or major depression. It aims to find the best combination for each person, including an injectable weight-management medication and a brain-stimulation option.
This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.